evipedia.ai ← Back to Review

Audit: QRS - Dehydrozingerone for Health & Longevity

Audit conducted on 18/07/2026 00:33 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 84
Failed 0
N/A 7
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All content traces to the ER (Conclusion, Protocol, Benefits, Risks, Interactions, Monitoring).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Cautious framing preserved (“no validated human dose”, “unproven hypothesis”, “Speculative” tier, “experimental”).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening/softening; pregnancy remains a hard contraindication.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Categories map correctly to their ER source sections.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No citations, NCT IDs, or brand names surfaced; the brand (ZinjaBurn) is reduced to “Manufacturer-suggested”.
1.6 The QRS does not introduce new attributions. 🟢 No new attributions introduced.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Measured, evidence-forward tone matching the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Meets the tone requirement.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents information without prescribing.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No directive medical advice; footer disclaimer present.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Information is presented, not recommended.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No direct address to the reader.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain language with inline lay explanations.
2.8 Information is presented in a concise and very compact manner 🟢 Content is compact and fits the card layout.
2.9 It DOES NOT address the reader directly 🟢 No second-person address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing suits an optimization-minded audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Consistent with such an audience.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not general-population framed.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting reflects the audience; healthy-baseline caveat retained implicitly via “unproven hypothesis”.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 Uses “Longevity”; no “anti-aging” language.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 No colloquial substitutions; plain-language phrasing in At-A-Glance is required by section 7.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”) 🟢 All fixed headings and labels are intact.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All template variable spans are present.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 No unaddressed spans were altered.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section mapped to the QRS is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Row/cell labels follow the ER’s terms.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels are faithful to the ER.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators; tier emphasis via bold labels and CSS.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content is condensed to fit one page.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment is the first element (lines 2-14).
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 YAML delimited by — / —.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; not rendered.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values trimmed; duration quoted due to colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: dehydrozingerone_2026-0718-0004_Opus_ER.md
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0718-0028
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 Single-word nickname “Opus”.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 4.8” — nickname + version only.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: dehydrozingerone_2026-0718-0004_Opus_QRS.html
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Frontmatter values are clean and consistent.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “Dehydrozingerone for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “Dehydrozingerone for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0718-0028 → 07/18/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 No extra header content present.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Directly distills the ER Conclusion.
7.2 [at_a_glance] is no longer than 60 words 🟢 54 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each phrase maps to a Conclusion passage.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain language (“cell-damaging molecules”, “helps muscle take up sugar”); no acronyms.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No statistics or effect sizes.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from that section (“Populations who should avoid it”).
8.2 [stop_items] represent the Contraindications from the ER 🟢 Pregnancy/breastfeeding, children, bleeding disorder, near surgery, organ impairment.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item is an <li>.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact. 🟢 Items are terse with no trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “~2 weeks of scheduled surgery” and “Significant” (liver/kidney) qualifiers preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation for contraindications.
8.7 If no [stop_items] are present the section is left empty N/A Stop items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from the ER interactions bullets.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Drug/supplement interactions listed; population contraindications excluded.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item is an <li>.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact. 🟢 Concise; no trailing clauses.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Named example-drug lists preserved in parentheses.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation for interactions.
9.7 If no [caution_items] are present the section is left empty N/A Caution items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Derived from the ER Therapeutic Protocol.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Dose, Timing, Form.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three actionable aspects are present.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All three action cells are populated from the ER.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 The ER provides one time-to-effect aspect (metabolic, weeks in animals), which is filled.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Single populated set corresponds to the metabolic benefit.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. 🟢 time_2 and time_3 are empty and set to display:none.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 time_1 label/value/sub populated from the ER.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER does provide time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Derived from Expected Benefits.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four variables present.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Short titles only.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parenthetical content carried over; “Conflicted” marker dropped.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high and benefits_medium set to display:none.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Derived from Potential Risks & Side Effects.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four variables present.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Short titles only.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parenthetical content carried over.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_high and risks_medium set to display:none.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Derived from the ER Monitoring Protocol.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 Fasting glucose, HbA1c, hs-CRP, ALT, Platelet count — all five listed with targets and rationale.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Baseline, 8–12 weeks, then every 6–12 months; matches the ER.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Derived from the ER’s qualitative markers.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 Mood, energy, digestive comfort, and unusual bruising/bleeding — all four listed.

Issues 18/07/2026 00:33

Pass rate 100.00%. No issues found.